H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress

Pharvaris advanced its hereditary angioedema program as the FDA accepted the deucrictibant IR New Drug Application, setting a PDUFA action date of April 23, 2027, while the EMA validated the marketing authorization and began review in July 2026. The pivotal Phase 3 CHAPTER-3 trial enrolled 85 patients (2:1) for deucrictibant XR once daily prophylaxis, with topline data expected in Q3 2026 and cash runway into 2028. On the financial side, the company ended Q2 2026 with €318M cash vs €292M at Dec. 31, 2025, after a €132.3M offering, while multiple firms reiterated Buy/Overweight calls and raised targets (e.g., $75 and $55), supporting the shares’ 48% 1-year return.

Analysis

PHVS has moved from a financing-and-platform story to a two-event binary. The near-term de-risking from the regulatory filing mainly caps downside, but it does not yet justify full peak-sales math; that still depends on whether the prophylaxis program shows enough efficacy and tolerability to compete in a market where convenience and persistence matter more than headline response rates. In other words, the stock is likely to trade on a higher floor now, but the ceiling is still set by CHAPTER-3.

The second-order winner, if the data are good, is not just PHVS but the whole oral HAE prophylaxis category: an effective once-daily option would pressure incumbents with injection burden or adherence friction. That would be most negative for oral competitors whose differentiation is already thin, and less so for entrenched biologics with strong physician loyalty. If the readout is merely adequate, the market may conclude this is a niche on-demand asset with limited commercial breadth, which would compress the implied probability of reaching the more ambitious sales cases.

Balance-sheet risk is muted, so the real tail risk is clinical, not financial. With runway extending well past the next catalyst, the main falsifier is a CHAPTER-3 miss on attack-rate reduction, rescue-medication use, or safety/QT follow-up; any delay or request for additional studies would likely knock 30%+ off the stock quickly. Over 6-18 months, the key question is whether PHVS can migrate from a single-asset valuation to a durable franchise multiple, which requires proof that the prophylaxis label can expand beyond a modest HAE niche.

Key Decisions for Investors

• Watchlist: add PHVS as a catalyst-driven long only on a 10-15% pullback ahead of Q3 2026 CHAPTER-3 data; upside can be 25-40% if efficacy is clean, but position size should be small because the readout is binary.
• Pair trade idea into the data: long PHVS / short BCRX as a relative-value expression on oral HAE prophylaxis differentiation; this works best if CHAPTER-3 shows superior durability and tolerability, and should be cut immediately if efficacy is only average.
• If options liquidity allows, use a limited-risk call spread in PHVS into the CHAPTER-3 catalyst rather than outright equity; target a 2:1 to 3:1 payoff with loss capped if the trial disappoints.
• Set a hard falsifier alert on any CHAPTER-3 delay or FDA/EMA information request; if that happens, expect the multiple to de-rate quickly despite the cash runway.